top of page

Youth Ministry

Public·113 members
Keith Osborne
Keith Osborne

Is Pfizer A Good Stock To Buy


As the major U.S. stock indices fell into bear territory in 2022, big pharma stocks quickly became an oasis for nervous investors -- in many cases thanks to their largely recession-proof business models, reliable cash flows, and dependable quarterly dividends.




is pfizer a good stock to buy


Download: https://www.google.com/url?q=https%3A%2F%2Furluso.com%2F2ufBYf&sa=D&sntz=1&usg=AOvVaw2M2eK1M2FvsEv6XvlFbcFC



One of the rare exceptions to this trend was Pfizer (PFE 1.04%). Last year, the drugmaker's shares sank by 10.4%, despite the company's stellar earnings growth over the course of the year. Unfortunately, Pfizer's stock hasn't been able to shake off this downward momentum with the change of the calendar year. The pharma titan's shares, in fact, have dropped by another 14.5% during the first four weeks of 2023.


Pfizer's breathtaking nosedive over the prior 13 months isn't all bad news -- at least not for bargain hunters. On the valuation side, the pharma titan's shares are now trading at a highly compressed price-to-earnings (P/E) ratio of 6.7. The industry average for this key valuation metric, by contrast, presently stands at 24.2. What's more, Pfizer's stock hasn't been this cheap, from a P/E standpoint, since 2014.


The drugmaker's declining share price has also resulted in its dividend yield ballooning to a notable 3.75% on an annualized basis. Within the large-cap pharmaceutical space, the average dividend yield currently sits at 3.27%. Pfizer stock thus offers one of the industry's more generous yields.


All things considered, Wall Street has probably gone overboard on its bearish sentiment toward Pfizer stock. Granted, the drugmaker is dealing with some strong headwinds from COVID-19 sales declines and a bevy of upcoming patent expirations.


But Pfizer's internal research and development engine has been firing on all cylinders lately, and it has the financial capacity to simply buy its way out of a jam if one or more key late-stage assets fail to land in the clinic. Meanwhile, investors can bank on the stock's above-average dividend yield as the company slowly works through these headwinds.


Pfizer (PFE 1.04%) announced its third-quarter results on Tuesday. While its shares moved a little higher after posting impressive numbers, the pharma stock is still down close to 20% year to date.


Bourla stated that Pfizer's acquisitions of Arena, Biohaven, Global Blood Therapeutics, and ReViral could generate more than one-third of this revenue goal. With strong cash flow and a massive cash stockpile of over $33 billion as of June 30, the company shouldn't have any problems continuing to wheel and deal.


For income investors, my view is that Pfizer remains a great stock to buy. The dividend yield stands north of 3.4%. Pfizer will almost certainly continue to prioritize its dividend program. Investors should be able to count on reliable dividend income for a long time to come.


In my opinion, Pfizer probably will more than offset the revenue impact of its upcoming LOEs. If the company delivers on its forecast, the stock should provide attractive total returns -- perhaps even enough to again get investors excited.


Pfizer (NYSE:PFE) has been one of the largest winners in the last two years, thanks to massive revenue gains from its COVID vaccine and drug. 2022 will be a gigantic year for the company, both in absolute terms and relative to how the company has performed in the past. But investors should know that this is an anomaly and that profits will likely decline to a more sustainable level in 2023 and beyond. It thus makes sense to take a longer-term view before chasing Pfizer's stock based on unsustainable levels of profitability.


Pfizer Inc. (NYSE:PFE) currently stands out to me as the best risk-adjusted choice to own for 2023 in the defensive pharmaceutical sector, and maybe the entire blue-chip universe trading on Wall Street. The minimal stock gain for 2022 has easily bested the S&P 500 -14% over the past 12 months. Yet, this result has not kept pace with Big Pharma gains as a group. The reason revolves around expectations for its COVID-19 vaccine and antiviral windfall in profits to dissipate over a year or two. The roundup summary is its stock price has been digesting outsized pandemic-related gains from 2021 this year.


Going into slower growth, defensive stocks like those in healthcare tend to do very well. Benefited incredibly from Covid. Great business. Used to be much more broad-based, but sold them all off. Drugs take a long time to produce. Great dividend yield.


In the last year, 25 stock analysts published opinions about PFE-N. 13 analysts recommended to BUY the stock. 8 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Pfizer Inc.


The Computershare CIP ("CIP") allows investors of Pfizer Inc. to directly purchase and sell shares of company common stock and reinvest dividends. You can learn more about the CIP by contacting Computershare. Please see details below.


Dividends are paid by check, or they may be directly deposited into a bank account of your choice. Most major domestic banks and financial institutions allow for direct deposit. To enroll in the Direct Deposit of Dividends Service, complete and sign an Authorization Form and send it with a voided check to Computershare. For informaton on dividend and stock split history, click here.


If your stock certificate is lost, stolen, or destroyed, notify Computershare immediately at (800) 733-9393. They will place a "stop transfer" on the certificate and give you instructions on how to replace your stock certificate. You will be asked to complete an Affidavit of Lost Stock Certificate. A surety bond and a premium of approximately 3% of the market value of the shares will also be required.


Book-entry form of registered ownership allows you to own shares without having paper stock certificates in your possession. You are the record owner and enjoy the same shareholder benefits as you would with certificated shares.


Book-entry ownership eliminates some of the problems associated with paper certificates such as storage and safety of securities. Book-entry shares also eliminate the requirement for physical movement of stock certificates at the time of sale or transfer of ownership.


If you hold your book-entry shares through the Shareholder Investment Program you will receive a statement at the end of every month in which an investment or other stock activity takes place. If you have book-entry shares but do not participate in the Shareholder Investment Program, you will receive a statement of your holdings on a yearly basis. You may, of course, request an additional statement at any time by contacting Computershare.


Yes. Simply send your certificates to Computershare with written instructions to deposit them in your account as book-entry items. Do not endorse the certificates or complete the assignment section. We recommend that you send your certificates by certified or registered mail and insure them for 3% of the market value of the stock.


You may request stock certificates for the whole shares in your book-entry account at any time. Simply contact Computershare with your request and a stock certificate for the requested number of whole shares will be sent to you within 7-10 business days.


The Direct Deposit of Dividends Service is available to you if your shares of Pfizer common stock are held in your own name. If your shares are held through a broker, you must first have the shares transferred into your own name in order to be eligible for the Pfizer Direct Deposit of Dividends Service.


If you have had a legal name change, you must re-register your shares. If your shares are held in a record account at Computershare, complete a Transfer of Ownership Form and send the form and your stock certificates to Computershare. If your shares are held in a book-entry or Shareholder Investment Program account, you still must complete and submit a Transfer of Ownership Form.


If your registered shares are held in certificate form: Complete a Transfer Request Form, which can be found here , and send the form and your stock certificates to Computershare, Pfizer's transfer agent. If your shares are held in book-entry form, you still must complete and submit a Transfer Request Form, which can be found here. If your shares are held by a bank or broker, please contact that firm for instructions.


Effective October 27, 2011 Pfizer Inc. completed its acquisition of Icagen, Inc. Pursuant to the terms of the merger, former Icagen shareholders will receive $6.00, in cash (without interest and less any applicable withholding and transfer taxes) for each share of Icagen common stock they owned as of the effective time of the merger.


Effective February 28, 2011 Pfizer Inc. completed its acquisition of King Pharmaceuticals, Inc. Pursuant to the terms of the merger, former King shareholders will receive $14.25, net in cash (without interest and less any required holding taxes) for each share of King common stock they owned as of the effective date.


Though corporate profits are high, and the stock market is booming, most Americans are not sharing in the economic recovery. While the top 0.1% of income recipients reap almost all the income gains, good jobs keep disappearing, and new ones tend to be insecure and underpaid.


A turning point was the wave of hostile takeovers that swept the country in the 1980s. Corporate raiders often claimed that the complacent leaders of the targeted companies were failing to maximize returns to shareholders. That criticism prompted boards of directors to try to align the interests of management and shareholders by making stock-based pay a much bigger component of executive compensation.


Despite the escalation in buybacks over the past three decades, the SEC has only rarely launched proceedings against a company for using them to manipulate its stock price. And even within the 25% limit, companies can still make huge purchases: Exxon Mobil, by far the biggest stock repurchaser from 2003 to 2012, can buy back about $300 million worth of shares a day, and Apple up to $1.5 billion a day. In essence, Rule 10b-18 legalized stock market manipulation through open-market repurchases. 041b061a72


About

Welcome to the group! You can connect with other members, ge...
bottom of page